Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.6984 -0.0248 (-3.43%) Market Cap: 178.71 Mil Enterprise Value: 73.46 Mil PE Ratio: 0 PB Ratio: 2.25 GF Score: 64/100

Adaptimmune Therapeutics PLC at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 04:15PM GMT
Release Date Price: $0.8799 (-2.23%)
Jem de los Santos JPMorgan Chase;Co.;Analyst

&-

Morning, and thank you for coming. My name is Jem de los Santos. I work in the investment banking practice at JPM based in London. Very pleased today to present Adrian Rawcliffe of Adaptimmune.

Adrian Rawcliffe Adaptimmune Therapeutics plc;CEO

Thanks, Jem, and thank you, everybody, for joining us. I'm Rawcliffe from the CEO of Adaptimmune, and I'm absolutely delighted to be here at the beginning of 2024. Because 2024 will be the year where Adaptimmune transforms from merely the pioneering force in bringing cell therapies for solid tumors into an integrated commercial cell therapy company, through the approval and launch of Afami-cel, the first engineered T-cell therapy for the treatment of solid tumors and the start of a sarcoma franchise that we believe will be highly valuable and a beachhead for getting cell therapies into the solid tumor space and becoming mainstream in that space.

This is the disclaimer which will cover the forward-looking statements. I plan on making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot